165 related articles for article (PubMed ID: 24548675)
1. The case for mistletoe in the treatment of laryngeal cancer.
Shakeel M; Trinidade A; Geider S; Ah-See KW
J Laryngol Otol; 2014 Mar; 128(3):302-6. PubMed ID: 24548675
[TBL] [Abstract][Full Text] [Related]
2. [Mistletoe therapy. An alternative cancer treatment].
Ernst E
MMW Fortschr Med; 2000 Nov; 142(45):52-3. PubMed ID: 11107826
[No Abstract] [Full Text] [Related]
3. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
[TBL] [Abstract][Full Text] [Related]
4. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
[TBL] [Abstract][Full Text] [Related]
5. [Mistletoe therapy in cancer treatment: pros and cons].
Wiebelitz KR; Beer AM; Heinrich B
MMW Fortschr Med; 2009 Nov; 151(46):30-1. PubMed ID: 20043390
[No Abstract] [Full Text] [Related]
6. [Value of mistletoe therapy in carcinoma patients].
Rostock M; Unger C
Internist (Berl); 1998 Dec; 39(12):1294-5. PubMed ID: 10198836
[No Abstract] [Full Text] [Related]
7. [Problems of randomized studies in complementary medicine demonstrated in a study on mistletoe treatment of patients with breast cancer].
Gerhard I; Abel U; Loewe-Mesch A; Huppmann S; Kuehn JJ
Forsch Komplementarmed Klass Naturheilkd; 2004 Jun; 11(3):150-7. PubMed ID: 15249749
[TBL] [Abstract][Full Text] [Related]
8. [Favorable long-term outcome with mistletoe therapy in a patient with centroblastic-centrocytic non hodgkin lymphoma].
Pierach CA
Dtsch Med Wochenschr; 2000 Aug; 125(31-32):958-60. PubMed ID: 10967963
[No Abstract] [Full Text] [Related]
9. [Mistletoe therapy is not consistent with good clinical practice].
Eckerdal G
Lakartidningen; 2014 Jan 29-Feb 4; 111(5):128-9. PubMed ID: 24624759
[No Abstract] [Full Text] [Related]
10. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial.
Friess H; Beger HG; Kunz J; Funk N; Schilling M; Büchler MW
Anticancer Res; 1996; 16(2):915-20. PubMed ID: 8687151
[TBL] [Abstract][Full Text] [Related]
11. Apparent response of small cell lung cancer to an extract of mistletoe and homoeopathic treatment.
Bradley GW; Clover A
Thorax; 1989 Dec; 44(12):1047-8. PubMed ID: 2559483
[TBL] [Abstract][Full Text] [Related]
12. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador).
Grossarth-Maticek R; Ziegler R
Eur J Med Res; 2008 Mar; 13(3):107-20. PubMed ID: 18499556
[TBL] [Abstract][Full Text] [Related]
13. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study.
Grossarth-Maticek R; Kiene H; Baumgartner SM; Ziegler R
Altern Ther Health Med; 2001; 7(3):57-66, 68-72, 74-6 passim. PubMed ID: 11347286
[TBL] [Abstract][Full Text] [Related]
14. [Vysorel/Isorel--cancer drug from Viscum album. Documentation No.20].
Kast A; Hauser SP
Schweiz Rundsch Med Prax; 1990 Mar; 79(11):332-4. PubMed ID: 2315589
[TBL] [Abstract][Full Text] [Related]
15. Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative.
Kaegi E
CMAJ; 1998 May; 158(9):1157-9. PubMed ID: 9597967
[No Abstract] [Full Text] [Related]
16. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study.
Bar-Sela G; Wollner M; Hammer L; Agbarya A; Dudnik E; Haim N
Eur J Cancer; 2013 Mar; 49(5):1058-64. PubMed ID: 23218588
[TBL] [Abstract][Full Text] [Related]
17. [Possibilities and limits of mistletoe therapy in cancer patients].
Hoffmann J
Arch Gynecol Obstet; 1987; 242(1-4):257-60. PubMed ID: 3688952
[No Abstract] [Full Text] [Related]
18. [Blood and tissue eosinophilia, mistletoe lectin antibodies and quality of life in a breast cancer patient undergoing intratumoral and subcutaneous mistletoe therapy].
Kröz M; Schad F; Matthes B; Pickartz H; Girke M
Forsch Komplementarmed Klass Naturheilkd; 2002 Jun; 9(3):160-7. PubMed ID: 12119512
[TBL] [Abstract][Full Text] [Related]
19. Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas.
Nishimura G; Tsukuda M; Horiuchi C; Satake K; Yoshida T; Nagao J; Kawakami M; Kondo N; Arai Y; Taguchi T; Matsuda H; Mikami Y
Auris Nasus Larynx; 2007 Dec; 34(4):499-504. PubMed ID: 17604583
[TBL] [Abstract][Full Text] [Related]
20. [Iscador--mistletoe extract for cancer treatment. Documentation No. 10].
Schweiz Rundsch Med Prax; 1988 Jan; 77(4):69-74. PubMed ID: 3279479
[No Abstract] [Full Text] [Related]
[Next] [New Search]